# This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

> **NCT01528735** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 25 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** BI 207127 NA
- **DRUG:** peginterferon
- **DRUG:** Ribavirin
- **DRUG:** Ribavirin
- **DRUG:** BI 207127 NA
- **DRUG:** BI 201335 NA
- **DRUG:** BI 201335 NA
- **DRUG:** peginterferon

## Key facts

- **NCT ID:** NCT01528735
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01528735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01528735, "This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01528735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*